340 related articles for article (PubMed ID: 24941980)
1. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
2. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Bedke J; Stenzl A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
[TBL] [Abstract][Full Text] [Related]
4. IMA901: a peptide vaccine in renal cell carcinoma.
Bedke J; Stenzl A
Expert Opin Investig Drugs; 2013 Oct; 22(10):1329-36. PubMed ID: 23899354
[TBL] [Abstract][Full Text] [Related]
5. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
[TBL] [Abstract][Full Text] [Related]
6. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
Dillman RO; Barth NM; VanderMolen LA; Garfield DH; De Leon C; O'Connor AA; Mahdavi K; Nayak SK
Cancer Biother Radiopharm; 2001 Feb; 16(1):47-54. PubMed ID: 11279797
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for renal cell cancer.
Yang JC; Childs R
J Clin Oncol; 2006 Dec; 24(35):5576-83. PubMed ID: 17158543
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic developments in renal cell cancer.
Prenen H; Gil T; Awada A
Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
[TBL] [Abstract][Full Text] [Related]
9. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
Patard JJ
Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
[No Abstract] [Full Text] [Related]
11. Short-term tumor cell lines from renal cell carcinoma for use as autologous tumor cell vaccines in the treatment of kidney cancer.
Dillman RO; Beutel LD; Cornforth AN; Nayak SK
Cancer Biother Radiopharm; 2000 Apr; 15(2):161-8. PubMed ID: 10803321
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic approaches for renal cancer.
Pizza G; de Vinci C; Viza D
Folia Biol (Praha); 2002; 48(5):167-81. PubMed ID: 12448765
[No Abstract] [Full Text] [Related]
13. Current immunotherapeutic strategies in renal cell carcinoma.
Amato RJ
Surg Oncol Clin N Am; 2007 Oct; 16(4):975-86, xi-xii. PubMed ID: 18022554
[TBL] [Abstract][Full Text] [Related]
14. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
15. Tailor-made renal cell carcinoma vaccines.
Dranoff G
Cancer Cell; 2012 Sep; 22(3):287-9. PubMed ID: 22975372
[TBL] [Abstract][Full Text] [Related]
16. Vaccines in renal cell carcinoma.
Kübler H; Vieweg J
Semin Oncol; 2006 Oct; 33(5):614-24. PubMed ID: 17045091
[TBL] [Abstract][Full Text] [Related]
17. [Tumor cell vaccination for treatment of renal cell carcinoma].
Kriegmair M; Oberneder R
Urologe A; 1995 May; 34(3):204-7. PubMed ID: 7610513
[TBL] [Abstract][Full Text] [Related]
18. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients.
Wang Z; Zhang Y; Liu Y; Wang L; Zhao L; Yang T; He C; Song Y; Gao Q
J Immunother; 2014 Jan; 37(1):43-50. PubMed ID: 24316555
[TBL] [Abstract][Full Text] [Related]
19. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
[TBL] [Abstract][Full Text] [Related]
20. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]